I have gone with a conservative 1% target penetration by end of 2025.
- Q1: 1 refill
- Q2: 2 refills
- Q3: 3 refills
- Q4: 4 refills
Revenue per Customer Calculation:
- $450 USD x 1.6 (USD/AUD) = AUD 720 per refill.
Now, let's calculate the revenue per customer for each quarter: ( Assumption 450USD *1.6 (USD/AUD)
- Q1: 1 refill = AUD 720 x 1 = AUD 720
- Q2: 2 refills = AUD 720 x 2 = AUD 1,440
- Q3: 3 refills = AUD 720 x 3 = AUD 2,160
- Q4: 4 refills = AUD 720 x 4 = AUD 2,880
- 5-6 Refills from 2026 onwards
Updated Table:
Metric Q1 2025 Q2 2025 Q3 2025 Q4 2025 Cumulative Customers 10,000 30,000 60,000 100,000 Customers Acquired 10,000 20,000 30,000 40,000 Cumulative Penetration Rate 0.10% 0.30% 0.60% 1.00% Revenue per Customer (AUD) AUD 720 AUD 1,440 AUD 2,160 AUD 2,880 Cumulative Revenue (AUD) AUD 7,200,000 AUD 43,200,000 AUD 129,600,000 AUD 288,000,000
EV/Revenue Multiple (5x) = 288m * 5 = 1.44B (MC) Divided by Shares O/s = 0.79c by YE
- Forums
- ASX - By Stock
- BOT
- Current And Future Valuation 2025
BOT
botanix pharmaceuticals ltd
Add to My Watchlist
0.00%
!
31.5¢

Current And Future Valuation 2025, page-57
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $617.6M |
Open | High | Low | Value | Volume |
32.5¢ | 33.0¢ | 31.5¢ | $1.783M | 5.561M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 460766 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 19200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 105225 | 0.310 |
7 | 200573 | 0.305 |
16 | 978125 | 0.300 |
9 | 424106 | 0.295 |
18 | 798899 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 10000 | 1 |
0.325 | 127612 | 4 |
0.330 | 279340 | 5 |
0.335 | 290014 | 6 |
0.340 | 158760 | 3 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online